▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis posted a whopping US$254 million sales in the European market in the first half of the year, data showed on July 25. According to the co...
[THE INVESTOR] Bukwang Pharmaceutical said on July 24 that its subsidiary Dyna Therapeutics plans to go public on the country’s secondary bourse KOSDAQ next year. Dyna Therapeutics, wholly owned b...
[THE INVESTOR] Korea has high potential to become a major part of the global biopharma business ecosystem with its openness for collaboration and swift clinical trial process, according to executive...
[THE INVESTOR] A patent licensing dispute between Reyon Pharmaceutical and ViroMed is intensifying as a gene therapy candidate developed by the latter is expected to become commercialized. Seou...
[THE INVESTOR] A civic activist group said on July 19 it has filed a complaint with the prosecution against the chief executive of Samsung BioLogics following Korea’s top financial regulator’s rulin...
[THE INVESTOR] Kolon Life Science said on July 18 that it has entered an agreement with a Chinese health care provider to export Invossa, an injectable cell gene therapy for osteoarthritis in a deal...
[THE INVESTOR] Johnson & Johnson subsidiary Janssen Pharmaceuticals will initiate new clinical trials for expanded use of HM12525A, a drug candidate originally developed by Hanmi Pharmaceutical , ...
[THE INVESTOR ] YD Global Life Science said on July 17 that it filed an application with the US Food and Drug Administration for phase 2a clinical trials of its diabetic retinopathy drug candidate Y...
[THE INVESTOR] Daewoong Pharmaceutical has hold its first ever non-deal roadshow to promote its botulinum toxin which is expected to be the first Botox biosimilar to hit the US market. The roadshow...
[THE INVESTOR] A long-standing controversy over Samsung BioLogics’ accounting practices has concluded for the time being as the country’s financial watchdog ruled that it clearly violated related ...
[THE INVESTOR] The Korean financial regulator said on July 12 it will refer Samsung BioLogics’ accounting “irregularity” to prosecutors after concluding that the contract drug manufacturer intenti...
[ THE INVESTOR] The Ministry of Food and Drug Safety said on July 12 it is testing a method to analyze cancer-causing residue in hypertension drugs’ key ingredient valsartan, manufactured by a Chin...
[THE INVESTOR] The financial regulator is set to hold its fifth review session on a suspected accounting breach by Samsung BioLogics, officials said on July 12. The session, which aims to decide...
[THE INVESTOR] Kolon TissueGene CEO Lee Woo-sok expressed confidence in making its gene threapy candidate Invossa a game changer in the osteoarthritis treatment market, following the US FDA’s approv...
[THE INVESTOR] Korea’s photoconductor drums manufacturer Mirae SCI said on July 9 that it has set up a biotechnology-focused joint venture with Israeli venture capital firm Yozma Group. Yozma BioSc...
The Investor’s Choice 2018 to crown top startups on Nov. 28
US hedge fund Elliot renews pressure on Hyundai
Ant Financial highlights SMEs, blockchain, global partnerships for further growth
Samsung to offer glimpse of foldable smartphone in Seoul
Game firms gear up to dazzle at G-Star 2018
Able C&C acquires Mefactory for W32b
Korean startup entrepreneur lives brewing dream
SK hynix introduces new DRAM chip
November 15, 2018
